Navigation Links
No Cancer Risk From Long-Acting Insulin: Studies
Date:6/12/2012

By Steven Reinberg
HealthDay Reporter

MONDAY, June 11 (HealthDay News) -- Three studies should squelch fears that taking a form of insulin called insulin glargine (Lantus) increases the risk of cancer, researchers say.

Prior research had suggested an increase in cancer risk with Lantus, an injectable drug used to treat diabetes. "But, the worry we had that Lantus might be associated with cancer seems not to be the case, and people should continue using insulin," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City, who wasn't involved in these studies.

Lantus is a long-acting insulin, meaning patients need only one shot a day, rather than multiple injections, and it's easy to use, Mezitis added.

People using glargine often have type 1 diabetes, a condition in which the body can't make insulin, which is needed to regulate the amount of sugar in the blood. People with type 2 diabetes, the form linked to being overweight and sedentary, may also take insulin if lifestyle and dietary changes don't control their blood-sugar levels.

In the United States, where obesity and type 2 diabetes are soaring, Mezitis said he expects to see many more insulin users in years to come.

In each study, researchers wanted to see if there was any connection between daily doses of insulin and cancer.

The results were scheduled for presentation Monday at a meeting of the American Diabetes Association in Philadelphia.

In one study, Laurel Habel, a research scientist at the Kaiser Permanente Northern California Division of Research, and colleagues looked at the risk of cancer among 115,000 patients taking either glargine or an intermediate-acting insulin called NPH. This is usually taken twice a day.

"We looked at prostate, breast and colon cancer and all cancers combined," Habel said. "We saw no evidence that there was any relationship between glargine and the risk of these cancers."

In addition, no risk of cancer was noted among patients who switched from another long-acting insulin to glargine or in people who started on glargine first, Habel said.

But, these findings are based on short-term use of the drugs -- median duration was less than 1.5 years -- and she said additional follow-up is needed to evaluate cancer risk over the long-term. Cancer can take years to decades to develop, Habel noted.

In another trial, researchers from the University of North Carolina (UNC) looked at the risk of cancer in more than 52,000 people taking glargine or NPH.

Over two years of follow-up, the researchers found no association between either form of insulin and the risk for any cancer.

The UNC team used data from the Northern European Study of Insulin and Cancer, which included more than 447,000 patients, and found no spike in cancer risk for glargine or any other insulin.

"There was absolutely no association at all between the risk of cancer and any form of insulin," researcher Peter Boyle, president of the International Prevention Research Institute in Lyon, France, said during a Monday press conference. The researchers had looked for risk of all cancers, plus risks for cancers of the breast, lung, pancreas, lung, colon and prostate.

"There was absolutely no causal association," he added.

In yet another study, Dr. Hertzel Gerstein, a professor of medicine at McMaster University in Hamilton, Ontario, Canada, and colleagues found no raised risk of cancer or heart disease in a study of insulin involving more than 12,500 participants.

"At the end of the day, the study showed that one injection of insulin a day had a neutral effect on heart attacks, strokes and deaths. In addition, it had no effect on other outcomes like cancers," Gerstein said.

No protective effects on cardiovascular health or cancer were seen from insulin either, according to the report, published in the June 11 online edition of the New England Journal of Medicine.

Data and conclusions presented at medical meetings should be considered preliminary until published in a peer-reviewed medical journal.

More information

For more information on diabetes, visit the American Diabetes Association.

SOURCES: Laurel Habel, Ph.D., research scientist, Kaiser Permanente Northern California Division of Research, Oakland, Calif.; Hertzel Gerstein, M.D., professor, medicine, McMaster University department of medicine, Hamilton, Canada; Spyros Mezitis, M.D., endocrinologist, Lenox Hill Hospital, New York City; June 11, 2012, news conference, Peter Boyle, Ph.D., president, International Prevention Research Institute, Lyon, France; June 11, 2012, presentations, American Diabetes Association meeting, Philadelphia; June 11, 2012, New England Journal of Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
No Cancer Risk From Long-Acting Insulin: Studies
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... "FCPX LUT ... quality of your footage," said Christina Austin - CEO of Pixel Film Studios. ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/25/2016)... ... May 25, 2016 , ... HealthPostures ... will join America's leading engineers at the American Society of Safety Engineers Conference ... Congress Center. , Engineers, speakers and exhibitors from more than 40 countries ...
(Date:5/24/2016)... ... May 24, 2016 , ... BTC Media, a ... event, Distributed: Health, to be held in Nashville, Tennessee on September 7, 2016. ... 24-hour Hackathon preceding the event will host teams from around the world, competing ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... a new corporate identity and website at its “Transforming Outcomes” User Conference in ... marketing enhancements reflect i2i’s ongoing success to set the market standard for meaningful ...
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... ... for the Surgery Center at Sentara Northern Virginia Medical Center located in Woodbridge, ... of the hospital’s surgical services into a single site. , The new 2 ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... New York , May 23, 2016 ... market report titled, " Exocrine Pancreatic Insufficiency Market - ... 2013 - 2023 ." According to the report, the ... a CAGR of 8.3% from 2015 to 2023 to ... insufficiency (EPI) is a condition characterized by the deficiency ...
Breaking Medicine Technology: